Hyperion DeFi, Inc. (HYPD) compared with its closest peers (XLO, IBO, RNAZ, TENX, GRCE): P/E 14.6 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $52.68M | -0.2 |
| Impact BioMedical Inc. (IBO) | $51.75M | 65.6 |
| TransCode Therapeutics, Inc. (RNAZ) | $50.20M | -0.1 |
| Tenax Therapeutics, Inc. (TENX) | $46.42M | -9.1 |
| Grace Therapeutics, Inc. (GRCE) | $46.28M | -9.9 |
| FILANA THERAPEUTICS, INC. (FLNA) | $46.27M | — |
| Seres Therapeutics, Inc. (MCRB) | $45.43M | 23.2 |
| Karyopharm Therapeutics Inc. (KPTI) | $44.57M | -0.4 |
| Silo Pharma, Inc. (SILO) | $43.59M | — |
| Veru Inc. (VERU) | $42.37M | -2.4 |
| Stock P/E | 14.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -32.9% |
| vs Industry | -14.2% |
HYPD overview · HYPD earnings · HYPD financials · HYPD KPIs · HYPD investor relations · HYPD ownership · HYPD filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.